Treatment Strategies for NSCLC Following Progression on Adjuvant Immunotherapy

Opinion
Video

Oncology experts from the University of Kansas discuss treatment strategies for both resectable and unresectable non-small cell lung cancer (NSCLC) following progression on adjuvant immunotherapy, providing valuable insights into navigating the challenges posed by this evolving clinical scenario.

CN_KC_SS_Seg05
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay up to date on recent advances in the multidisciplinary approach to cancer.

      Subscribe Now!
      Recent Videos
      Future work may focus on determining strategies for protecting the health of patients who undergo surgery during climate disasters.
      Studying How Climate Disaster Responses Impact Post-NSCLC Surgery Survival
      A study assessed whether physicians would keep patients who received NSCLC surgery in the hospital longer as an improvisational strategy after wildfires.
      Hospital Length of Stay After NSCLC Surgery Higher With Wildfire Exposure
      6 experts are featured in this series.
      Future Therapies for ALK+ Metastatic NSCLC
      6 experts are featured in this series.
      Evaluating ALK Inhibitors in Treatment Sequencing and Testing
      6 experts are featured in this series.
      Treatment Strategies in Disease Progression in ALK+ NSCLC
      6 experts are featured in this series.
      Patient Factors Considered when Choosing Treatment Selection
      6 experts are featured in this series.
      KRAS+ NSCLC: Treatment Management Strategies
      6 experts are featured in this series.
      Is There a Role for KRAS Inhibitors in the First-Line Treatment of NSCLC?
      6 experts are featured in this series.
      KRAS G12 Inhibitor Treatment Options
      6 experts are featured in this series.
      Clinical Experience of Lorlatinib ALK+ NSCLC Patients
      Related Content
      A futility analysis showed that ociperlimab was unlikely to reach the primary end point of overall survival as part of the phase 3 AdvanTIG-302 trial.

      Developers Terminate Clinical Program for Ociperlimab in Lung Cancer

      Russ Conroy
      April 3rd 2025
      Article

      A futility analysis showed that ociperlimab was unlikely to reach the primary end point of overall survival as part of the phase 3 AdvanTIG-302 trial.

      The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

      Improving NSCLC Surgery Recovery After Climate Disaster Exposure

      Leticia Nogueira, PhD, MPH
      March 31st 2025
      Podcast

      The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

      AI, Immunotherapy, More Key Lung Cancer Advances Highlighted at 2025 ELCC

      AI, Immunotherapy, More Key Lung Cancer Advances Highlighted at 2025 ELCC

      Ariana Pelosci
      April 1st 2025
      Article

      An expert panel at ELCC 2025 reviews the MARIPOSA trial's implications for first-line therapy in EGFR-mutated NSCLC and broader advancements.

      Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

      Navigating Management and Dosing Considerations for Amivantamab in NSCLC

      Daniel Morgensztern, MD;Mary Ellen Flanagan, NP ;Janelle Mann, PharmD, BCOP
      February 10th 2025
      Podcast

      Experts from Washington University in St. Louis discuss trial results and infusion-related reaction management for amivantamab in EGFR-mutated NSCLC.

      Findings from the phase 3 CROWN trial evaluating lorlatinib in ALK-positive non–small cell lung cancer revealed a sustained PFS benefit with the agent.

      Integrating Lorlatinib Into First-Line ALK-Positive NSCLC Treatment

      Roman Fabbricatore
      March 29th 2025
      Article

      Findings from the phase 3 CROWN trial evaluating lorlatinib in ALK-positive non–small cell lung cancer revealed a sustained PFS benefit with the agent.

      Leticia Nogueira, PhD, MPH, highlights how facilities exposed to wildfires tend to have longer lengths of stay for patients undergoing surgery for NSCLC.

      Prioritizing Climate Hazard Preparedness Following NSCLC Surgery

      Russ Conroy
      March 28th 2025
      Article

      Leticia Nogueira, PhD, MPH, highlights how facilities exposed to wildfires tend to have longer lengths of stay for patients undergoing surgery for NSCLC.